Li Jin, Jia Zhuxia, Wang Rongxuan, Xiao Bitao, Cai Yanan, Zhu Tianshu, Wang Weiya, Zhang Xinyue, Fan Shu, Fan Xiaolong, Han Wenmin, Lu Xuzhang
Department of Hematology, Changzhou No. 2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, China.
Beijing Key Laboratory of Gene Resource and Molecular Development, Laboratory of Neuroscience and Brain Development, Beijing Normal University, Beijing, China.
Front Oncol. 2024 May 10;14:1357996. doi: 10.3389/fonc.2024.1357996. eCollection 2024.
Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells in bone marrow. Upfront identification of tumor subgroups with specific biological markers has the potential to improve biologically-driven therapy. Previously, we established a molecular classification by stratifying multiple myeloma into two subtypes with a different prognosis based on a gene module co-expressed with MCL-1 (MCL1-M).
Gene Ontology (GO) analysis with differentially expressed genes was performed to identify signal pathway. Drug sensitivity was analyzed using the OncoPredict algorithm. Drug sensitivity of different myeloma cell lines was detected by CCK8 and flow cytometry. RNA-seq was performed on drug-sensitive cell lines before and after adriamycin treatment. RT-qPCR was used to further verify the sequencing results. The expression of γ-H2AX and dsDNA in sensitive and resistant cell lines was detected by immunofluorescence method.
In our study, we demonstrated that MCL1-M low MM were more sensitive to anthracyclines. We treated different myeloma cell lines with doxorubicin and discovered the association of drug sensitivity with IFN signaling. Herein, we demonstrate that the doxorubicin-sensitive myeloma cell line showed significant DNA damage and up-regulated expression of genes related to the IFN response, which was not observed in drug-insensitive cell lines.
Our results suggest that the active IFN signaling pathway may serve as a marker for predicting chemotherapy sensitivity in patients with myeloma. With our MCL1-M molecular classification system, we can screen patients with a potentially good response to the interferon signaling pathway and provide individualized treatment for MM. We propose IFN-a as adjuvant therapy for patients with myeloma sensitive to anthracyclines to further improve the therapeutic effect and prolong the survival of patients.
多发性骨髓瘤(MM)是一种由骨髓中克隆性浆细胞异常增殖引起的恶性浆细胞疾病。利用特定生物标志物对肿瘤亚组进行前期鉴定有可能改善基于生物学的治疗。此前,我们基于与MCL-1共表达的基因模块(MCL1-M),将多发性骨髓瘤分为两个预后不同的亚型,从而建立了一种分子分类方法。
对差异表达基因进行基因本体论(GO)分析以识别信号通路。使用OncoPredict算法分析药物敏感性。通过CCK8和流式细胞术检测不同骨髓瘤细胞系的药物敏感性。对阿霉素处理前后的药物敏感细胞系进行RNA测序。使用RT-qPCR进一步验证测序结果。通过免疫荧光法检测敏感和耐药细胞系中γ-H2AX和双链DNA的表达。
在我们的研究中,我们证明MCL1-M低表达的MM对蒽环类药物更敏感。我们用阿霉素处理不同的骨髓瘤细胞系,发现了药物敏感性与IFN信号传导之间的关联。在此,我们证明阿霉素敏感的骨髓瘤细胞系显示出显著的DNA损伤以及与IFN反应相关基因的表达上调,而在药物不敏感的细胞系中未观察到这种情况。
我们的结果表明,活跃的IFN信号通路可能作为预测骨髓瘤患者化疗敏感性的标志物。利用我们的MCL1-M分子分类系统,我们可以筛选出对干扰素信号通路可能有良好反应的患者,并为MM提供个体化治疗。我们建议将IFN-α作为对蒽环类药物敏感的骨髓瘤患者的辅助治疗,以进一步提高治疗效果并延长患者生存期。